Novo Nordisk Biotech Fund

Corporate Venture Capital Fund

Novo Nordisk Biotech Fund is Novo Nordisk’s internal Corporate Venture Capital Fund, responsible for equity investments in biotechnology companies. Investments are made globally in companies focused on discovering and developing innovative therapies within areas of current therapeutic interest to Novo Nordisk.

Established in 2001, Novo Nordisk Biotech Fund has invested more than USD 60 million in biotechnology companies. Novo Nordisk Biotech Fund typically invests USD 2 to 8 million per company per financing round.

Investment focus areas

Early stage as well as later stage companies, operating within the areas of:

Inflammation
Diabetes
Obesity
Haemostasis
Protein Delivery Systems and Devices
Enabling Technologies

Novo Nordisk Biotech Fund offers

Venture capital funding. Early to late stage
Strong Commitment
Access to Novo Nordisk’s R&D competencies

Contact

Johannes Jensen
Vice President, Novo Nordisk Biotech Fund
Direct Phone: ++45 4442 4922

Further information
For further information and contact information, please go to Novo Nordisk Biotech Fund’s web site: www.biotechfund.novonordisk.com